503B outsourcing facility

A 503B outsourcing facility is the higher-regulation tier of compounding. The category was created in 2013 by the Drug Quality and Security Act, passed after a compounding pharmacy shipped contaminated steroid injections that caused a nationwide meningitis outbreak. Facilities that register under section 503B are primarily overseen and inspected by FDA, on a risk-based schedule, and are subject to increased quality standards.

The difference that matters most is manufacturing standards. FDA states that drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements, while drugs compounded under section 503A in a state-licensed pharmacy are not. CGMP is the same framework that governs approved drug manufacturing: validated processes, documented batch records, environmental controls, stability testing.

A second structural difference: 503B facilities may compound in batches without a patient-specific prescription in hand and ship to clinics and providers, which is why they supply hospitals and larger telehealth operations. A 503A pharmacy compounds for a named patient.

The confusion to avoid is reading 503B as equivalent to FDA-approved. It is not. FDA is explicit that compounded drugs — from either tier — are not FDA-approved, meaning the agency has not reviewed the specific product for safety, effectiveness or quality before marketing. 503B raises the manufacturing floor; it does not convert a compounded drug into an approved one. FDA has also issued warnings to outsourcing facilities in this space, including over repackaging retatrutide, a substance that cannot lawfully be compounded at all.

FDA publishes a public list of registered outsourcing facilities, and checking a name against it takes a minute. Ask your provider which facility makes your medication, then look it up. Our pharmacy legitimacy lookup and compounded impurity review cover what the paperwork can and cannot tell you.